Vertex completes $5.0B acquisition of Alpine Immune Sciences on May 20, 2024

VERTEX PHARMACEUTICALS INC / MA

Acquisition of Alpine for approximately $5.0B in equity value completed.
Alpine now operates as a wholly owned subsidiary of Vertex.
Accounting treatment for the acquisition to be finalized during Q2 2024.
Merger effected via tender offer followed by a Section 251(h) merger.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.